U.S. DEGENERATIVE DISC DISEASE TREATMENT MARKET ANALYSIS

U.S. Degenerative Disc Disease Treatment Market, by Treatment (Epidural Steroid Injections, Narcotics (Morphine, Methadone Hydrochloride, Codeine, Hydrocodone, Tramodol, Oxycodone, and Others), Orthobiologics (Includes Biomolecular/Gene Therapy, Cell-based Therapy, and Tissue-engineered Products) Phase I, Phase II, and Phase III), by Disease Indication (Early Stage, Mid Stage, and Late Stage), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Aug 2021
Code : CMI4590
Pages :179
Formats :
Excel and PDF
Industry : Pharmaceutical

U.S. Degenerative Disc Disease Treatment MarketSize and Trends

The U.S. degenerative disc disease treatment market is estimated to have around 2.644 Mn patients suffering from degenerative disc disease (DDD) in 2021 and is expected to exhibit a CAGR of 5.9% during the forecast period (2021-2028).

Increasing cause of lower back pain & neck pain in adults and increasing geriatric population is expected to drive the market growth during the forecast period.

Increasing cause of lower back pain & neck pain in adults and increasing geriatric population in the U.S. is expected to drive the growth of the degenerative disc disease treatment market over the forecast period. For instance, according to the article published in the National Center of Biotechnology Information in May 2017, among adults 60% to 80% would experience back pain and 20% to 70% would experience neck pain that would interfere with their daily activities during their lifetime in the U.S.